Cargando…
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m–2 week–1 and leucovorin 500 mg m–2 week–1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify the possible mechanism underlying the improved activity of HDFL compared with conventional 5-FU r...
Autores principales: | Yeh, K-H, Yeh, S-H, Hsu, C-H, Wang, T-M, Ma, I-F, Cheng, A-L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363429/ https://www.ncbi.nlm.nih.gov/pubmed/11076661 http://dx.doi.org/10.1054/bjoc.2000.1456 |
Ejemplares similares
-
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract
por: Hsu, C, et al.
Publicado: (2004) -
5-Fluorouracil targets thymidylate synthase in the selective suppression of T(H)17 cell differentiation
por: Wang, Juan, et al.
Publicado: (2016) -
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
por: Iacopetta, B, et al.
Publicado: (2001) -
Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001) -
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
por: Yeh, K H, et al.
Publicado: (2005)